Breathing Treatment Options for Patients with Tachycardia and Atrovent Allergy

First-Line Treatment Options

The American College of Allergy, Asthma, and Immunology recommends short-acting beta-agonists like albuterol or levalbuterol as the first-line breathing treatment options for patients with tachycardia who are allergic to ipratropium bromide (Atrovent) 1, 2
Albuterol is the primary recommended treatment for patients with respiratory distress who cannot use ipratropium, and it can be delivered via metered-dose inhaler (MDI) with spacer or nebulizer, with both delivery methods showing comparable efficacy 2
Short-acting beta-agonists are the treatment of choice for relief of acute respiratory symptoms and prevention of exercise-induced bronchoconstriction, according to the American Academy of Allergy, Asthma, and Immunology 1

The American Heart Association suggests that magnesium sulfate can be considered as an adjunct therapy for patients with severe respiratory distress, and when combined with nebulized beta-adrenergic agents, IV magnesium sulfate can moderately improve pulmonary function with only minor side effects 2
For patients with severe refractory bronchospasm, the American College of Chest Physicians recommends considering IV magnesium at the standard adult dose of 2 g administered over 20 minutes 2
Systemic corticosteroids should be considered for patients with asthma exacerbations, as they are the only treatment proven effective for the inflammatory component, and early administration hastens the resolution of airflow obstruction, according to the National Asthma Education and Prevention Program 2

For patients on beta-blockers who experience severe bronchospasm, the American Academy of Allergy, Asthma, and Immunology recommends considering glucagon (1-5 mg IV over 5 minutes followed by infusion) as it can help relax bronchial smooth muscle independent of beta-blockade 3, 4
In patients with severe cardiac disease where beta-agonists pose significant risk, the American Heart Association suggests considering epinephrine or terbutaline administered subcutaneously as alternative bronchodilators 2

For patients with persistent tachycardia despite treatment, the American College of Cardiology recommends considering continuous cardiac monitoring, especially if multiple doses of beta-agonists are required 4
If the patient develops worsening tachycardia or other cardiac symptoms during treatment, the American Heart Association suggests considering reducing the dose or frequency of beta-agonist administration 2